Clinical trials: Cardiac Infarct
Myocardial Infarction, Ischemic Heart Disease
Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
This study is recruiting patients already scheduled for a single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) test.
- Trial name
- REGA-1102 (NCT01499654)
- Testing
- Half-dose of the Tc99-m sestamibi (Cardiolite)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Edwin Wu
Stroke, Myocardial Infarctions
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications.
- Trial name
- NCT01586975
- Testing
- Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Northwestern University
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Myocardial Infarction
Impact of a Corrie Cardiac Rehabilitation Program
In this randomized clinical trial, the researchers are investigating whether a multi-component virtual/hybrid cardiac rehabilitation program will improve functional status, cholesterol level, overall cardiovascular health…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Myocardial Ischemia, Coronary Artery Occlusion
- Trial name
- mTECH-Rehab (NCT05238103)
- Testing
- Corrie Hybrid Cardiac Rehabilitation Program
- Where
- United States
- Volunteers
- 259 people
- Sponsor
- Johns Hopkins University
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Unstable Angina, Myocardial Infarction
Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes
The timing of intervention study is a prospective, randomized, international, multicentre comparison of the relative efficacy, safety, and cost effectiveness of a management strategy of coronary angiography and intervention…
- Trial name
- TIMACS (NCT00552513)
- Testing
- Early Coronary Intervention, Delayed Coronary Intervention
- Where
- Canada
- Volunteers
- 3,031 people
- Sponsor
- Population Health Research Institute
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary…
- Trial name
- NCT00684021
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Coronary Syndrome, Myocardial Infarction
Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation
Physical exercise training appears effective for low to moderate patients assigned to cardiac rehabilitation. However, adherence to cardiac rehabilitation is low and physical activity levels often drop after attending the last…
- Trial name
- FIT@Home (NCT01732419)
- Testing
- Home-based training, Centre-based training
- Where
- Netherlands
- Volunteers
- 90 people
- Sponsor
- Maxima Medical Center
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction, Arthritis
Mechanisms of Action of Acetaminophen
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen.
- Trial name
- NCT00646906
- Testing
- Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Shock, Cardiogenic, High Risk Percutaneous Coronary Interventions
Synchronized Cardiac Assist for Cardiogenic Shock
The purpose of this study is to collect prospective safety and performance information for the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung failure or in high risk percutaneous…
- Trial name
- NCT02697006
- Testing
- i-cor Synchronized Cardiac Assist Device
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Xenios AG
Smoking Cessation, Acute Coronary Syndrome
Post Acute Coronary Event Smoking Study
Smoking and depressed mood are both predictive of mortality following Acute Coronary Syndrome. However, to date, no counseling treatment has been designed to target smoking cessation and manage mood in this population.
- Trial name
- PACES (NCT01964898)
- Testing
- Behavioral Activation (BA), Standard Smoking Cessation Counseling, Nicotine patch
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The Miriam Hospital
ST Elevation Myocardial Infarction, Inflammatory Response
Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction
The overall primary objective of the PULSE-MI trial is to test the hypothesis that administration of single-dose glucocorticoid pulse therapy in the pre-hospital setting reduces final infarct size in patients with ST-segment…
- Conditions
- ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury, Myocardial Injury
- Trial name
- PULSE-MI (NCT05462730)
- Testing
- Methylprednisolone, Isotonic saline
- Where
- Denmark
- Volunteers
- 530 people
- Sponsor
- Thomas Engstrom
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline